The UK pharma industry could save billions by investing in digital technologies

In association with

INVEST

IN TECH

ISSUE 71 I JUNE 2018

Tracing the history of mumps

Gene editing tool CRISPR's potential

Inside Swiss pharma

Go to article: Home | Invest in TechGo to article: In this issueGo to article: Gerteis Company InsightGo to article: GerteisGo to article: ContentsGo to article: DJAGo to article: NewsGo to article: MedelpharmGo to article: Biotech M&A: will the 2018 surge last?Go to article: NSFGo to article: Can the gene and cell therapy revolution scale up?Go to article: Haselmeier GmbH Company InsightGo to article: Haselmeier GmbH Go to article: Gut instinct: how common drugs affect the microbiomeGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Tracing the story of mumps: a timelineGo to article: Molnar Company InsightGo to article: MolnarGo to article: Inside Swiss pharma: the ideal environment for successGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: MoehsGo to article: Could digital tech unlock billions in savings for pharma companies?Go to article: EcocoolGo to article: CRISPR: a seismic shift in gene editingGo to article: Mestra AG (Endress + Hauser)Go to article: EventsGo to article: Pfanstiehl Inc Company InsightGo to article: Pfanstiehl Inc.Go to article: Next issueGo to article: Niconex Medical LtdGo to article: Alpex Pharma SAGo to article: Pall Biotech Company InsightGo to article: Pall BiotechGo to article: AtoZ-CRO GmbHGo to article: WIKA - Disaster preventionGo to article: Bea TechnologiesGo to article: BaxterGo to article: SuezGo to article: Raland Compliance Partners